Denali Therapeutics Inc. (DNLI) — SEC Filings
Denali Therapeutics Inc. (DNLI) — 41 SEC filings. Latest: 8-K (Mar 31, 2026). Includes 18 8-K, 11 SC 13G/A, 5 10-Q.
View Denali Therapeutics Inc. on SEC EDGAR
Overview
Denali Therapeutics Inc. (DNLI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 25, 2026: Denali Therapeutics Inc. filed an 8-K on March 25, 2026, under Item 7.01, Regulation FD Disclosure, indicating a significant announcement or event that the company wants to make public. This filing includes an exhibit, EX-99.1, which is likely a press release detailing the undisclosed information. F
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 36 neutral, 2 mixed. The dominant filing sentiment for Denali Therapeutics Inc. is neutral.
Filing Type Overview
Denali Therapeutics Inc. (DNLI) has filed 18 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 3 SC 13G, 11 SC 13G/A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of DNLI's 24 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$126.9M |
| EPS | N/A |
| Debt-to-Equity | 0.14 |
| Cash Position | $90.96M |
| Operating Margin | N/A |
| Total Assets | $1.06B |
| Total Debt | $129.42M |
Key Executives
- Delaware
- Massachusetts
- December 29, 2023
Industry Context
Denali Therapeutics operates in the highly competitive biotechnology sector, focusing on developing therapeutics for neurodegenerative and lysosomal storage diseases. This field is characterized by significant R&D investment, long development cycles, and high failure rates. Key industry trends include advancements in genetic medicine, personalized therapies, and strategic partnerships between biotech firms and larger pharmaceutical companies to share risk and leverage expertise.
Top Tags
disclosure (6) · regulation-fd (5) · institutional-ownership (5) · Biotechnology (4) · regulatory-filing (4) · biotech (4) · amendment (4) · 8-K (3) · 10-Q (3) · biotechnology (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $126.9M | Increased from $107.19M in Q3 2024, an 18.39% increase in loss. |
| Net Loss (YTD Sep 2025) | $383.99M | Increased from $308.02M in YTD Sep 2024, a 24.65% increase in loss. |
| Cash & Cash Equivalents | $90.96M | Decreased from $174.96M at Dec 31, 2024, indicating significant cash burn. |
| Research & Development Expenses (Q3 2025) | $101.95M | Increased from $98.24M in Q3 2024, reflecting continued investment. |
| General & Administrative Expenses (Q3 2025) | $35.48M | Increased from $24.95M in Q3 2024, contributing to higher operating costs. |
| Total Assets | $1.06B | Decreased from $1.37B at Dec 31, 2024, reflecting asset utilization and losses. |
| Outstanding Common Shares | 146,661,833 | As of October 31, 2025, indicating potential for dilution with future raises. |
| Q2 2025 Revenue | $30.5M | 32.5% decrease from Q2 2024's $45.2M |
| Q2 2025 Net Loss | $120.1M | 13.5% increase from Q2 2024's $105.8M |
| H1 2025 Revenue | $62.3M | 30.8% decrease from H1 2024's $90.1M |
| H1 2025 Net Loss | $245.7M | 16.7% increase from H1 2024's $210.5M |
| Cash and Equivalents | $1.05B | Total liquidity as of June 30, 2025, supporting R&D |
| Revenue Decrease | 32.5% | Year-over-year decline in Q2 2025 revenue |
| Net Loss Increase | 13.5% | Year-over-year increase in Q2 2025 net loss |
| SEC File Number | 001-38311 | Identifies the company's filing with the SEC. |
Forward-Looking Statements
- {"claim":"Denali Therapeutics Inc. may see increased institutional investor interest following this disclosure.","entity":"Denali Therapeutics Inc.","targetDate":"Q2 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Denali Therapeutics Inc. (DNLI)?
Denali Therapeutics Inc. has 41 recent SEC filings from Jan 2024 to Mar 2026, including 18 8-K, 11 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DNLI filings?
Across 41 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 36 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Denali Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Denali Therapeutics Inc. (DNLI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Denali Therapeutics Inc.?
Key financial highlights from Denali Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DNLI?
The investment thesis for DNLI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Denali Therapeutics Inc.?
Key executives identified across Denali Therapeutics Inc.'s filings include Delaware, Massachusetts, December 29, 2023.
What are the main risk factors for Denali Therapeutics Inc. stock?
Of DNLI's 24 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Denali Therapeutics Inc.?
Recent forward-looking statements from Denali Therapeutics Inc. include guidance on {"claim":"Denali Therapeutics Inc. may see increased institutional investor interest following this disclosure.","entity.